Effect of intrapartum hyoscine butylbromide and sodium bicarbonate on spontaneous vaginal birth in nulliparous women after induction of labour (SAINT): multicentre randomised placebo controlled factorial trial

OBJECTIVE: To determine whether intrapartum hyoscine butylbromide, sodium bicarbonate, and their combination increase the rate of spontaneous vaginal birth in nulliparous women undergoing induction of labour. DESIGN: Multicentre, randomised, double blind, placebo controlled, 2×2 factorial phase 3 trial (SAINT). SETTING: 11 Norwegian hospitals providing comprehensive obstetric care. PARTICIPANTS: Nulliparous women aged 18-50 years with a singleton live fetus in cephalic presentation at term with an indication for induction of labour. INTERVENTIONS: Participants were randomly assigned (1:1:1:1) to oral sodium bicarbonate (4×1 g per dose) plus intravenous hyoscine butylbromide (20 mg per dose), oral sodium bicarbonate plus intravenous placebo, oral placebo plus intravenous hyoscine butylbromide, or double placebo. The investigational medicinal product was administered at the onset of active labour and repeated every four hours to a maximum of three doses. MAIN OUTCOME MEASURE: Spontaneous vaginal birth (no instrumental or caesarean delivery). RESULTS: Between 4 January 2023 and 29 January 2025, 3094 nulliparous women were randomised, and 2963 comprised the full analysis set. Spontaneous vaginal birth occurred in 57% (422/741) in the bicarbonate plus hyoscine butylbromide arm, 61% (445/734) in the bicarbonate arm, 61% (449/741) in the hyoscine butylbromide arm, and 56% (422/747) in the double placebo arm. Marginal risk differences for spontaneous vaginal birth compared with double placebo were -0.2 (95% confidence interval -5.1 to 4.7; P=0.93) percentage points for combined treatment, 3.1 (-1.7 to 8.0; P=0.21) percentage points for bicarbonate, and 4.0 (-0.8 to 8.9; P=0.10) percentage points for hyoscine butylbromide. Serious adverse events were similar between groups, and no treatment related serious morbidity or deaths were observed. CONCLUSIONS: No clear evidence was found that intrapartum hyoscine butylbromide, sodium bicarbonate, or their combination increased spontaneous vaginal birth compared with placebo. Although small beneficial effects cannot be excluded, the findings do not support routine intrapartum use of either agent to facilitate spontaneous vaginal birth after induction of labour. TRIAL REGISTRATION: European Clinical Trials Database (EudraCT; 2021-000392-37); EU Clinical Trials Information System (CTIS; EU CT number 2024-511848-55-00); ClinicalTrials.gov (NCT05719467).

Authors

Institutions

Publication Details

Journal
BMJ
Published
2026-11-18
DOI
https://doi.org/10.1136/bmj-2026-101069
Primary Topic
Maternal and Perinatal Health Interventions
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effect of intrapartum hyoscine butylbromide and sodium bicarbonate on spontaneous vaginal birth in nulliparous women after induction of labour (SAINT): multicentre randomised placebo controlled factorial trial

Tonje Lippert, Jörg Kessler, Katrine Sjøborg, Åse Torunn Revholdt Pettersen et al.
3 links
BMJ
Maternal and Perinatal Health Interventions
article

Effect of intrapartum hyoscine butylbromide and sodium bicarbonate on spontaneous vaginal birth in nulliparous women after induction of labour (SAINT): multicentre randomised placebo controlled factorial trial

Tonje Lippert, Jörg Kessler, Katrine Sjøborg, Åse Torunn Revholdt Pettersen, Ingvil Krarup Sørbye, Camilla Haavaldsen, Lisa Tangnes Leeves, Anne Molne Kjøllesdal, Anne Flem Jacobsen, Trond Melbye Michelsen, Ragnar Kvie Sande, Aslak Vimme Solhoff, Elisabeth Magnussen, Nina Gunnes Nilsen, Marte Ween-Velken
article en

Abstract

OBJECTIVE: To determine whether intrapartum hyoscine butylbromide, sodium bicarbonate, and their combination increase the rate of spontaneous vaginal birth in nulliparous women undergoing induction of labour. DESIGN: Multicentre, randomised, double blind, placebo controlled, 2×2 factorial phase 3 trial (SAINT). SETTING: 11 Norwegian hospitals providing comprehensive obstetric care. PARTICIPANTS: Nulliparous women aged 18-50 years with a singleton live fetus in cephalic presentation at term with an indication for induction of labour. INTERVENTIONS: Participants were randomly assigned (1:1:1:1) to oral sodium bicarbonate (4×1 g per dose) plus intravenous hyoscine butylbromide (20 mg per dose), oral sodium bicarbonate plus intravenous placebo, oral placebo plus intravenous hyoscine butylbromide, or double placebo. The investigational medicinal product was administered at the onset of active labour and repeated every four hours to a maximum of three doses. MAIN OUTCOME MEASURE: Spontaneous vaginal birth (no instrumental or caesarean delivery). RESULTS: Between 4 January 2023 and 29 January 2025, 3094 nulliparous women were randomised, and 2963 comprised the full analysis set. Spontaneous vaginal birth occurred in 57% (422/741) in the bicarbonate plus hyoscine butylbromide arm, 61% (445/734) in the bicarbonate arm, 61% (449/741) in the hyoscine butylbromide arm, and 56% (422/747) in the double placebo arm. Marginal risk differences for spontaneous vaginal birth compared with double placebo were -0.2 (95% confidence interval -5.1 to 4.7; P=0.93) percentage points for combined treatment, 3.1 (-1.7 to 8.0; P=0.21) percentage points for bicarbonate, and 4.0 (-0.8 to 8.9; P=0.10) percentage points for hyoscine butylbromide. Serious adverse events were similar between groups, and no treatment related serious morbidity or deaths were observed. CONCLUSIONS: No clear evidence was found that intrapartum hyoscine butylbromide, sodium bicarbonate, or their combination increased spontaneous vaginal birth compared with placebo. Although small beneficial effects cannot be excluded, the findings do not support routine intrapartum use of either agent to facilitate spontaneous vaginal birth after induction of labour. TRIAL REGISTRATION: European Clinical Trials Database (EudraCT; 2021-000392-37); EU Clinical Trials Information System (CTIS; EU CT number 2024-511848-55-00); ClinicalTrials.gov (NCT05719467).

BMJVol. 395
Oslo University Hospital (NO), University Hospital of North Norway (NO), University of Oslo (NO), Norwegian University of Science and Technology (NO), Stavanger University Hospital (NO), Akershus University Hospital (NO), Vestre Viken Hospital Trust (NO), Haukeland University Hospital (NO), St Olav's University Hospital (NO), Østfold Hospital Trust (NO), Sørlandet Sykehus (NO), University of Bergen (NO)
Ministry of Education, India, Sykehuset Østfold, Haukeland Universitetssjukehus, Akershus Universitetssykehus
Good health and well-being
Maternal and Perinatal Health Interventions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon